KDR and cancer: VEGFR-2 has an advantage of the weak expression in the healthy tissue and overexpression is reported in several types of cancer namely, breast cancer, prostate cancer, colon cancer, cervical cancer, NSCLC, kidney clear cell cancer, brain glioma, bladder carcinoma, pancreatic cancer, oral cancer, skin melanoma oesophageal cancer, and ovarian cancer9,.10